


Four-times daily ASA more effective in post-CABG patients

January 16 2015



(HealthDay)—For patients undergoing coronary artery bypass graft (CABG) surgery, four-times daily acetyl-salicylic acid (ASA) seems more effective than once-daily 81 mg or 325 mg ASA, according to a study published online Dec. 27 in the *Journal of Thrombosis and Haemostasis*.

Jeremy S. Paikin, M.D., from McMaster University in Hamilton, Canada, and colleagues conducted a randomized study involving 100 [patients](#) undergoing CABG [surgery](#) to compare the effects of ASA 81 mg once-daily, ASA 325 mg once-daily, and ASA 81 mg four-times daily. The authors compared the effect on serum thromboxane B₂ (TXB₂) suppression and arachidonate-induced [platelet](#) aggregation.

The researchers found that platelet counts decreased after surgery, reached a nadir on day two, then increased gradually. On the second or

third postoperative day there was near complete suppression of TXB₂; levels increased on subsequent days. Patients receiving ASA 81 mg once-daily had the most marked increase, while the increase was less evident with four-times daily ASA 81 mg. Median TXB₂ levels were lower on postoperative day four with four-times daily ASA 81 mg versus once-daily ASA 81 mg or 325 mg. Suppression of platelet aggregation was more effective with ASA given four-times daily versus ASA 81 mg or 325 mg once-daily.

"Four-times daily ASA is more effective than ASA 81 mg and 325 mg once-daily at suppressing serum TXB₂ formation and platelet aggregation immediately following CABG surgery," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: Four-times daily ASA more effective in post-CABG patients (2015, January 16)
retrieved 6 May 2024 from
<https://medicalxpress.com/news/2015-01-four-times-daily-asa-effective-post-cabg.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
